DOI: 10.4244/EIJ-D-18-00666R

Reply to the Letter to the Editor “Is it time to abandon drug-eluting stents for saphenous venous graft percutaneous coronary intervention?”

Islam Y. Elgendy1, MD; Ahmed N. Mahmoud1, MD; Emmanouil S. Brilakis2, MD, PhD; Anthony A. Bavry1,3, MD, PhD

We appreciate the interest of Sethi et al1 in our meta-analysis2. Sethi et al argue that there are several issues with the meta-analysis that could lead to the misinterpretation of the findings. First, they suggest that the sensitivity analysis excluding DELAYED RRISC3 showed a possible benefit with drug-eluting stents (DES). While this analysis might be statistically significant, there needs to be a scientific rationale for how a sensitivity analysis is conducted. The usual scenario is to exclude the largest trial and determine if the overall interpretation remains the same. In this case the exclusion of the smallest trial found a positive association; however, it was not consistent with the other sensitivity analyses excluding every other trial. Collectively, one cannot conclude that this sensitivity analysis would challenge the overall conclusion. Second, Sethi et al point out that performing a subgroup analysis by censoring the events at 12 months might yield a strong trend to suggest benefit of DES. However, the interaction within the subgroup analysis performed by Sethi et al is non-significant (p=0.06). In our analysis2, we included the cumulative events at a longer follow-up (i.e., beyond 12 months) rather than just censoring the events at 12 months to include the totality of events4. Importantly, our findings are concurrent with the largest trial to date comparing both devices (i.e., ISAR-CABG) which showed benefit with DES at 12 months5; however, this benefit was lost at five years, which is probably due to the higher attrition of efficacy in the DES group and the expected time-related graft degeneration6. These results are also supported in the recently published DIVA trial, which used contemporary second-generation DES and yet showed no benefit with DES at a median of 2.7 years7. In summary, the findings from our meta-analysis as well as the two large randomised trials on this topic dispute the safety concerns with DES which were seen in the DELAYED RRISC trial3, and suggest that there is no clear benefit for DES (even second-generation DES) over bare metal stents regarding long-term outcomes.

Conflict of interest statement

E. Brilakis reports consulting/speaker honoraria from Abbott Vascular, Amgen, Asahi, CSI, Elsevier, GE Healthcare, and Medicure, research support from Boston Scientific and Osprey, and that his spouse was an employee of Medtronic. A. Bavry discloses the following relationship – honorarium from the American College of Cardiology. The other authors have no conflicts of interest to declare.


References

Volume 15 Number 2
Jun 20, 2019
Volume 15 Number 2
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV12I16A314 Mar 20, 2017
Iteration of second-generation drug-eluting stents: the missing piece of evidence
Palmerini T and Biondi-Zoccai G
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved